
Expres²ion's joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent

Expres²ion Biotech Holding AB and its affiliate Expres²ion Biotechnologies ApS ("Expres²ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step forward for the project and documenting the patentability of the virus-like-particle (VLP) technology platform. After final approval, the patent will be valid at least 20 years from the priority date, 15-01-2015.

"This is a major milestone for AdaptVac, and in particular strengthens the company's position in negotiations with potential development partners for the AV001 breast cancer project. It furthermore adds credibility in general to the platform and any additional projects from AdaptVac's project portfolio," says Expres²ion's CEO Dr. Steen Klysner.

AdaptVac has filed patent applications for its HER2 breast cancer vaccine in all major and upcoming commercially relevant markets, including the USA and Europe. The divisional patent application that was allowed by the U.S. patent office is titled "Virus-like particle with efficient epitope display".

Strong worldwide market potential in breast cancer

Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US\$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is tailored to be highly competitive both in terms of cost and efficacy, thus aiming at a significant market share.

About AdaptVac ApS

AdaptVac is a joint venture between Expres²ion Biotechnologies and NextGen Vaccines, combining Expres²ion's platform with novel proprietary and groundbreaking virus-like particle (VLP) technology developed at the University of Copenhagen. The company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.

Certified Adviser

Sedermera Fondkommission is appointed as Certified Adviser for Expres²ion.

For further information about Expres²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

This press release contains information that Expres²ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on September 10, 2018.

About Expres²ion

Expres²ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, Expres², that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, Expres²ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.